KR20070041514A - 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민대사산물 - Google Patents

5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민대사산물 Download PDF

Info

Publication number
KR20070041514A
KR20070041514A KR1020077000822A KR20077000822A KR20070041514A KR 20070041514 A KR20070041514 A KR 20070041514A KR 1020077000822 A KR1020077000822 A KR 1020077000822A KR 20077000822 A KR20077000822 A KR 20077000822A KR 20070041514 A KR20070041514 A KR 20070041514A
Authority
KR
South Korea
Prior art keywords
compound
formula
alkyl
disorder
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077000822A
Other languages
English (en)
Korean (ko)
Inventor
요우추 왕
치아-쳉 쇼
로날드 찰스 베르노타스
충-츠 폴 왕
핑 차이
쯔 왕
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35033547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070041514(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20070041514A publication Critical patent/KR20070041514A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020077000822A 2004-06-23 2005-06-21 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민대사산물 Withdrawn KR20070041514A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58229004P 2004-06-23 2004-06-23
US60/582,290 2004-06-23

Publications (1)

Publication Number Publication Date
KR20070041514A true KR20070041514A (ko) 2007-04-18

Family

ID=35033547

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077000822A Withdrawn KR20070041514A (ko) 2004-06-23 2005-06-21 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민대사산물

Country Status (19)

Country Link
US (1) US7498327B2 (cg-RX-API-DMAC7.html)
EP (1) EP1758898A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008504267A (cg-RX-API-DMAC7.html)
KR (1) KR20070041514A (cg-RX-API-DMAC7.html)
CN (1) CN1976928A (cg-RX-API-DMAC7.html)
AR (1) AR049449A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005258025A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512540A (cg-RX-API-DMAC7.html)
CA (1) CA2570818A1 (cg-RX-API-DMAC7.html)
CR (1) CR8825A (cg-RX-API-DMAC7.html)
EC (1) ECSP067096A (cg-RX-API-DMAC7.html)
IL (1) IL180198A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007000182A (cg-RX-API-DMAC7.html)
NO (1) NO20070065L (cg-RX-API-DMAC7.html)
PA (1) PA8637801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060303A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006146923A (cg-RX-API-DMAC7.html)
TW (1) TW200606148A (cg-RX-API-DMAC7.html)
WO (1) WO2006002125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
DK1455779T3 (da) * 2001-12-20 2006-10-30 Wyeth Corp Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
WO2004078719A1 (ja) * 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity

Also Published As

Publication number Publication date
AU2005258025A1 (en) 2006-01-05
ECSP067096A (es) 2007-02-28
CR8825A (es) 2007-08-28
US20060003945A1 (en) 2006-01-05
PA8637801A1 (es) 2006-06-02
TW200606148A (en) 2006-02-16
BRPI0512540A (pt) 2008-03-25
WO2006002125A1 (en) 2006-01-05
IL180198A0 (en) 2007-06-03
AR049449A1 (es) 2006-08-02
MX2007000182A (es) 2007-03-23
JP2008504267A (ja) 2008-02-14
CA2570818A1 (en) 2006-01-05
NO20070065L (no) 2007-01-04
US7498327B2 (en) 2009-03-03
EP1758898A1 (en) 2007-03-07
CN1976928A (zh) 2007-06-06
PE20060303A1 (es) 2006-05-19
RU2006146923A (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
KR100985140B1 (ko) 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민 유도체
DE69434294T2 (de) Proteinkinase c-inhibitoren
JP4307073B2 (ja) 5−ヒドロキシトリプトアミン−6リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物
EP3333157B1 (en) Vinyl compounds as fgfr and vegfr inhibitors
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
RU2592285C2 (ru) Селективные ингибиторы гликозидазы и их применение
JP2016537369A (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
EP4285996A2 (en) Inhibitors of activin receptor-like kinase
EP0747353A2 (en) Indole derivatives
KR20030088508A (ko) 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴옥시-, -티옥시- 및 -아미노벤즈아졸 유도체
BR112019018688A2 (pt) derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
EP3560928B1 (en) Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
KR20080059297A (ko) 전압-개폐 나트륨 채널의 조절제로서의 4급알파-아미노카르복스아미드 유도체
WO2005047252A1 (en) Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
US7498327B2 (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
US6727270B2 (en) Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
EP0808316B9 (en) Vasoconstrictive substituted 2,3-dihydro-1,4-dioxinopyridines
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
HK1065949B (en) Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
HK40011966B (en) Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
HK40011966A (en) Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
HK1074047A1 (zh) 嶄新的咪唑化合物、其製備方法及藥物用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid